4-氰基苯硼酸 | 126747-14-6

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氰基苯硼酸
• 中文别名: 4-苯腈硼酸；对氰基苯硼酸；4-氰苯硼酸；4-腈基苯硼酸；4-氰基苯基硼酸
• 英文名称: 4-cyanophenylboronic acid
• 英文别名: 4-cyanobenzeneboronic acid；p-cyanophenylboronic acid；p-cyanobenzeneboronic acid；(para-cyano)phenylboronic acid；4-cyanobenzoboronic acid；4-cyanphenylboronic acid；4-cyanophenyl boronic；4-cyanoboronic acid；phenylboronic acid；(4-cyanophenyl)boronic acid
• CAS: 126747-14-6
• 化学式: C₇H₆BNO₂
• mdl: MFCD01318968
• 分子量: 146.941
• InChiKey: CEBAHYWORUOILU-UHFFFAOYSA-N

物化性质

• 熔点：
  >350 °C (lit.)
• 沸点：
  355.9±44.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO、甲醇（少许）
• 稳定性/保质期：
  如果按照规定使用和储存，则不会分解，目前没有已知的危险反应。请避免与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.45
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xi
• 安全说明：
  S22,S24/25,S26,S37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2931900090
• 危险品运输编号：
  UN3439
• 危险类别：
  6.1
• 包装等级：
  III
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  密封，在0-6 ºC下保存

SDS

Name:	4-Cyanophenylboronic Acid Material Safety Data Sheet
Synonym:	None Known
CAS:	126747-14-6

Section 1 - Chemical Product MSDS Name:4-Cyanophenylboronic Acid Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
126747-14-6	4-Cyanophenylboronic Acid	ca. 100	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a dry area. Keep refrigerated. (Store below 4C/39F.)

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 126747-14-6: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: > 300 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H6BNO2
Molecular Weight: 146.94

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, light, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents, acids, strong bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, boron oxides.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 126747-14-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Cyanophenylboronic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 126747-14-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 126747-14-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 126747-14-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

4-氰基苯硼酸作为一种常见的偶联试剂，广泛应用于与卤苯发生Suzuki-Miyaura偶联反应合成联苯的研究。近年来，关于4-氰基苯硼酸合成联苯的报道日益增多。

应用

4-氰基苯硼酸可以参与多种类型的偶联反应，包括C-C、C-N和C-O类型，用于合成各类有价值的化合物。

用途

主要用于Suzuki-type交叉偶联反应。

反应信息

• 作为反应物：
  描述：

  4-氰基苯硼酸 在 N-氯代丁二酰亚胺 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以98%的产率得到对氯苯甲腈
  参考文献：
  名称：

  高效多相铜催化芳基硼酸的氯脱硼，生成氯代芳烃

  摘要：

  的芳基硼酸与廉价的A高效多相铜催化chlorodeboronation Ñ氯琥珀酰亚胺（NCS）中的溶液在MeCN中的10％（摩尔）的存在下实现的大号脯氨酸官能MCM-41固定化铜（我）络合物[MCM-41 -大号-脯氨酸-CuCl]在温和的条件下，以优异的收率产生各种芳基氯化物。事实证明，该方法可耐受各种官能团，并且特别适用于将缺电子的芳基硼酸转化为芳基氯化物，这种转化在没有铜催化的情况下效率低下。可以通过简单过滤反应溶液来回收这种多相铜催化剂，并循环至少10次而不会降低活性。

  DOI：

  10.1039/c6ra25666j
• 作为产物：
  描述：

  4-溴苯腈 在 正丁基锂 、 硼酸三甲酯 作用下， 以 四氢呋喃 为溶剂， 生成 4-氰基苯硼酸
  参考文献：
  名称：

  Wavelength Conversion Lanthanide(III)-cored Complex for Highly Efficient Dye-sensitized Solar Cells

  摘要：

  由于短波长的光在紫外区的吸收有限，这些 DSSC 无法有效地用于发电，因此首次成功设计和合成了作为波长转换材料的镧系（III）有芯配合物，用于高效染料敏化太阳能电池。由于黑色染料（BD）在较短波长处的光吸收相对较弱，因此被选为敏化剂。BD/WCM 器件的整体转换效率显著提高，即使添加的 WCM 相对较少。与 DCA 一样，WCM 对 $V_{oc}$ 的增强可能与抑制注入电子和 $I_3{^-}$ 离子之间的电子重组有关。此外，WCM 还显著提高了短路电流密度，具有很强的紫外光收集效应。从 Eu(III)-cored 复合物到 $TiO_2$ 薄膜的能量转移是通过染料实现的，因此注入 $TiO_2$ 表面的电子数量增加，即短路电流密度增加。因此，BD/WCM 敏化太阳能电池表现出卓越的器件性能，在 AM 1.5 阳光下的转换效率提高了 1.22 倍：基于 BD/WCM 的 DSSC 的光电性能值非常高，$J_{sc}$为 17.72 mA/$cm^2$，$V_{oc}$为 720 mV，转换效率为 9.相比之下，标准 DSSC 的 $J_{sc}$ 为 15.53 mA/$cm^2$，$V_{oc}$ 为 689 mV，100 mW $cm^{-2}$ 时的转换效率为 7.58%。因此，Eu(III)掺杂复合物有望成为高效染料敏化太阳能电池的新型波长转换共吸附剂，通过能量转移过程改善紫外光收集。摘要应为概述文章内容的一个单独段落。

  DOI：

  10.5012/bkcs.2011.32.8.2743

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Synthesis of a Novel Library of 1-Substituted Pyrido[1,2-a]benzimidazoles
  作者：Satyanarayana Gadde、Yun Cheuk Leung、Mohan Bhadbade、Belamy B. Cheung、David StC. Black、Naresh Kumar

  DOI：10.1071/ch20173

  日期：——

  The reactivity and synthesis of new analogues of pyrido[1,2-a]benzimidazoles have been explored. Twenty-three derivatives bearing phenoxy, thiophenoxy, aniline, and aryl groups at the 1-position were successfully synthesised in 25–91 % yield, via nucleophilic substitution, Buchwald–Hartwig amination, and Suzuki coupling type processes. Solvent free synthetic protocols were employed to achieve the nucleophilic

  已经研究了吡啶并[1,2- a ]苯并咪唑的新类似物的反应性和合成。通过亲核取代，Buchwald-Hartwig胺化和Suzuki偶联类型工艺，成功合成了1位上带有苯氧基，噻吩氧基，苯胺和芳基的23种衍生物，收率25-91％。采用无溶剂的合成方案，通过空间需求中间体（7a）上的供电子基团或适度吸电子基团实现苯胺的亲核取代。在这项工作期间，一个不寻常的多环杂环被鉴定为副产物：二聚双（吡啶并[1,2- a ]苯并咪唑）。
• [EN] OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS D'OXAZOLE UTILES COMME INHIBITEURS DE FAAH
  申请人：MERCK & CO INC

  公开号：WO2010017079A1

  公开（公告）日：2010-02-11

  The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些噁唑衍生物，其可用作脂肪酸酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• Cu(OAc)2-Mediated Cross-Coupling Reaction of Benzophenone N,N,N-Trimethylhydrazonium Salts and Aryl Boronic Acids
  作者：Mitsuru Kitamura、Yu Tokuda、Norifumi Tashiro、Tatsuo Okauchi

  DOI：10.1071/ch12350

  日期：——

  Cu(OAc)2-mediated coupling of benzophenone N,N,N-trimethylhydrazonium salts and aryl boronic acids proceeded to afford N-aryl imines.

  Cu（OAc）2介导的二苯甲酮N，N，N-三甲基hydr盐与芳基硼酸的偶联反应得到N-芳基亚胺。
• [EN] PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS<br/>[FR] PYRAZOLOPYRIMIDINES TENANT LIEU D'INHIBITEURS DE KINASES DEPENDANTES DE LA CYCLINE
  申请人：SCHERING CORP

  公开号：WO2004022561A1

  公开（公告）日：2004-03-18

  In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

  在其多种实施方式中，本发明提供了一类新型的吡唑并[1,5-a]嘧啶化合物，作为细胞周期依赖性激酶的抑制剂，以及制备这类化合物的方法，含有一种或多种这类化合物的药物组合物，制备包含一种或多种这类化合物的药物配方的方法，以及利用这类化合物或药物组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。